GlaxoSmithKline

The article contains a PDF file structure with metadata and viewer preferences.

GSK presents abstracts on RSV vaccine safety, immunogenicity, and disease burden in older adults, along with studies on pertussis, meningococcal, and herpes zoster vaccines. Also included are abstracts on GSK's infectious disease medicines, focusing on urinary tract infections and antimicrobial resistance, and ViiV Healthcare's portfolio, featuring HIV treatment and prevention with long-acting injectables.

GSK’s Benlysta and Aurinia’s Lupkynis have advanced lupus nephritis treatment, but unmet needs persist. Roche’s Gazyva (obinutuzumab) showed potential in Phase III REGENCY trial, addressing key challenges like proteinuria and steroid dependence. Gazyva could become the second biologic for LN, challenging Benlysta’s market dominance. Lupkynis remains a niche option for high proteinuria, but Gazyva’s trial success may shift this dynamic. Future competition from AZ’s Saphnelo and Novartis’ ianalumab is expected post-2025.

GSK’s Benlysta and Aurinia’s Lupkynis have advanced lupus nephritis treatment, but unmet needs remain. Roche’s Gazyva (obinutuzumab) showed significant complete renal response in Phase III REGENCY trial, potentially addressing key challenges like proteinuria and steroid dependence. If approved, Gazyva could rival Benlysta and Lupkynis, with market impact expected before competition from AZ’s Saphnelo and Novartis’ ianalumab.

GSK shares rose 5% after resolving 93% of Zantac cancer lawsuits for up to $2.2 billion. Plaintiffs unanimously recommend accepting the settlement, expected by H1 2025. GSK denies Zantac increases cancer risk and settles with Valisure for $70 million, pending DOJ approval.

GSK will pay up to £1.7billion to settle claims that its heartburn drug Zantac caused cancer, ending a five-year legal saga.

Jenna Fischer discusses breast cancer diagnosis and treatment; Nobel Prize in chemistry awarded to David Baker, Demis Hassabis, and John Jumper for computational protein design; human placentas used to heal burns; medical transport helicopter crash kills three in Kentucky; Trump secretly sent COVID tests to Putin in 2020; Danco Laboratories seeks FDA approval for mifepristone in miscarriage management; FDA rejects dasiglucagon for congenital hyperinsulinism; physical activity reduces depression in cancer patients; COVID linked to increased risk of heart attack, stroke, and death; U.S. to screen travelers from Rwanda for Marburg virus; high suicide attempts among LGBTQ+ women; 3% of U.S. high school students identify as transgender; CDC survey shows high rates of sadness and suicide ideation among adolescents; RSV vaccine sales drop; GSK's RSV vaccine efficacy declines; hundreds of unknown viruses found on toothbrushes and shower heads; exoskeleton manufacturer refuses to help paraplegic; over 250 entities pledge to stock naloxone for opioid overdoses.

GSK's Phase III AReSVi-006 trial of Arexvy RSV vaccine showed 62.9% cumulative efficacy against lower respiratory tract disease over three seasons, with 67.4% against severe cases. The vaccine's safety profile aligned with previous data, and common adverse events included pain at the injection site, fatigue, and headaches.

DelveInsight's Menopause Market Insights, Epidemiology, and Market Forecast-2034 report analyzes market trends, epidemiology, and emerging therapies in the US, EU4, UK, and Japan. Key companies include GlaxoSmithKline, Pfizer, Bayer, and others. The market size was ~USD 10,968 million in 2022, with hormonal therapy dominating but expected to decline as non-hormonal therapies gain prevalence. Notable therapies include VEOZAH, a non-hormonal treatment approved by the FDA in 2023.

GSK's Arexvy, the first RSV vaccine, showed 62.9% cumulative efficacy over three RSV seasons against RSV-LRTD in adults 60+; 67.4% against severe RSV-LRTD. Efficacy includes different RSV subtypes, age groups, and medical conditions. Revaccination may be needed to maintain protection. The vaccine was approved in the US in May 2023 for adults 60+ and is under review for those 50-59 at risk.